MYGN
ミリアド・ジェネティックス
MYGN
ミリアド・ジェネティックス
On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just three months later, the Company cut guidance to $770-$790 million and adjusted EBITDA guidance was su
Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript
New published data shows Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for prostate cancer.